I still think that, but for some reason these tumors aren't shrinking enough to get partial responses. That's all the market sees. I think the multiple inject Ph II will change this and be a totally different trial from an efficacy standpoint. Hopefully they'll use adjuvants too. I think they can hit at least 30% ORR in their Ph IIs which is a huge success. But, time... That's somewhere in 2016. A lot can happen in these smid cap bios when you have to wait. And given manufacturing for L in Germany is limited, and they need vacc for the trial first and foremost, I don't think Hospital Exemption is going to move the pps very much for a while either. Though an early halt for efficacy is quite possible this year imo.
The logical thing to do then is buy some puts up here at $8 as a hedge, keeping shares as a core, and then should it drop, look for a place where it settles and then close out those puts for a profit and buy more shares at a lower price with them. Like in the $6s or even $5s again if the market gets ornery.
News 
Market Data 
Discover 
AI
